# An Unusual Case of Primary Plasma Cell Leukemia Presenting As Pericardial Effusion

**Authors:** Ahmed Qaedi, Ethan Barnes, Ali Hachem, Farrah Ibrahim

PMC · DOI: 10.7759/cureus.92483 · Cureus · 2025-09-16

## TL;DR

A rare case of plasma cell leukemia presented as pericardial effusion in a 58-year-old woman, highlighting the disease's varied symptoms and poor prognosis.

## Contribution

This paper presents a unique clinical case of primary plasma cell leukemia manifesting as pericardial effusion.

## Key findings

- Plasma cell leukemia can present with pericardial effusion as a primary symptom.
- The patient showed initial response to treatment but later became refractory.
- The case underscores the aggressive nature and poor survival outcomes of plasma cell leukemia.

## Abstract

Plasma cell leukemia represents the rarest form of plasma cell dyscrasias arising from monoclonal proliferation of plasma cells in peripheral blood. Its aggressive natural history raises a significant therapeutic challenge. We present a case of a 58-year-old female who presented with a cough accompanied by exertional dyspnea. Further radiological investigations revealed a circumferential pericardial effusion. A pericardiocentesis was performed, resulting in the drainage of 650 cc of hemorrhagic pericardial fluid. Cytology revealed monoclonal plasma cells expressing CD38 and CD138 with cytoplasmic lambda light chain restriction. A bone marrow biopsy disclosed a hypercellular marrow with a monoclonal plasma cell population of 33%. Treatment was initiated with intravenous dexamethasone and weekly subcutaneous injections of bortezomib, followed by outpatient cycles consisting of bortezomib, lenalidomide, daratumumab, and dexamethasone, with a good initial response. However, five months later, the plasma cell leukemia became refractory to treatment, and the patient passed away from septic shock secondary to community-acquired pneumonia. This case illustrates the variable presentations of plasma cell leukemia, as well as its poor prognosis. Further research is warranted to optimize therapeutic regimens and enhance overall survival.

## Linked entities

- **Proteins:** CD38 (CD38 molecule), SDC1 (syndecan 1)
- **Chemicals:** dexamethasone (PubChem CID 5743), bortezomib (PubChem CID 387447), lenalidomide (PubChem CID 216326)
- **Diseases:** plasma cell leukemia (MONDO:0018689), pericardial effusion (MONDO:0001370)

## Full-text entities

- **Genes:** CD38 (CD38 molecule) [NCBI Gene 952] {aka ADPRC 1, ADPRC1, cADPR1}, SDC1 (syndecan 1) [NCBI Gene 6382] {aka CD138, SDC, SYND1, syndecan}
- **Diseases:** Pericardial Effusion (MESH:D010490), Plasma Cell Leukemia (MESH:D007952), plasma cell dyscrasias (MESH:D010265), cough (MESH:D003371), septic shock (MESH:D012772), dyspnea (MESH:D004417), pneumonia (MESH:D011014)
- **Chemicals:** bortezomib (MESH:D000069286), dexamethasone (MESH:D003907), lenalidomide (MESH:D000077269), daratumumab (MESH:C556306)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12530953/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12530953/full.md

## References

18 references — full list in the complete paper: https://tomesphere.com/paper/PMC12530953/full.md

---
Source: https://tomesphere.com/paper/PMC12530953